Fed Pullback Pledge...
Health Care: Drugs
Immunogen Inc. (IMGN: NASDAQ)
$15.96 -0.42 | -2.56%
06/19/13 - 04:00 PM ET
Company Income Statement
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Sales | 16.36M | 19.30M | 13.94M | 27.99M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 16.36M | 19.30M | 13.94M | 27.99M |
| Selling, General, and Administrative Expenses | 20.42M | 16.04M | 14.90M | 13.90M |
| Research & Development | 69.19M | 63.45M | 50.28M | 45.90M |
| Operating Income before D & A (EBITDA) | -73.26M | -60.19M | -51.24M | -31.82M |
| Depreciation & Amortization | 3.66M | 3.96M | 3.86M | 4.02M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | -62.00K | 1.91M | 58.00K | -221.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -76.97M | -62.23M | -55.04M | -36.06M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -76.97M | -62.23M | -55.04M | -36.06M |
| Income Taxes | 0.00 | 0.00 | -265.00K | -100.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -73.32M | -58.27M | -50.91M | -31.94M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -73.32M | -58.27M | -50.91M | -31.94M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -73.32M | -58.27M | -50.91M | -31.94M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-73.32M | -58.27M | -50.91M | -31.94M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -73.32M | -58.27M | -50.91M | -31.94M |
| Basic EPS from Continuing Ops. | -0.95 | -0.85 | -0.87 | -0.63 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.95 | -0.85 | -0.87 | -0.63 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.95 | -0.85 | -0.87 | -0.63 |
| Basic Normalized Net Income/Share | -0.95 | -0.85 | -0.87 | -0.63 |
| EPS fr Continuing Ops. | -0.95 | -0.85 | -0.87 | -0.63 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.95 | -0.85 | -0.87 | -0.63 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.95 | -0.85 | -0.87 | -0.63 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.95 | -0.85 | -0.87 | -0.63 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with IMGN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserJKE 1
- UserWatch List - Healthcare / B...
- UserCR
- UserASCO 2010
- UserPART 7 JPMorgan 28th Annual...
- UserStockPot
Latest IMGN Headlines from TheStreet
- ImmunoGen Breaks Below 200-Day Moving Average - Notable For IMGN 04.18.13 | 04:04 pm
- 'Mad Money' Lightning Round: Buy, Buy, Buy Toll Brothers 04.17.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 04.05.13 | 07:04 pm
- Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX 04.05.13 | 06:04 am
- ImmunoGen CEO Confident After Strong Q1
04.02.13 | 03:04 pm - Cramer's 'Mad Money' Recap: Focus on Making Money 02.26.13 | 08:02 pm
- Cramer's 6 Stocks in 60 Seconds: IMGN ISRG AZO BMRN WEN CAT 02.22.13 | 10:02 am
- Analysts' Actions: AKS BBBY IMGN RIG LIFE 01.28.13 | 08:01 am
- 2013 FDA Drug Approval Decision Calendar 12.19.12 | 09:12 am
- 3 Stocks I Saw on TV 12.11.12 | 08:12 am
Press Releases for IMGN
- ImmunoGen, Inc. Announces Webcast Of Its Analyst And Investor Community Meeting On April 12, 2013 - Business Wire 03.12.13 | 06:03 am
- ImmunoGen, Inc. Announces FDA Approval Of Kadcyla (Ado-Trastuzumab Emtansine; Also Known As T-DM1) - Business Wire 02.22.13 | 09:02 am
- ImmunoGen, Inc. Attains Patient Enrollment Milestone In IMGN901 NORTH Trial - Business Wire 02.12.13 | 06:02 am
- ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences - Business Wire 02.05.13 | 01:02 pm
- ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results And Provides Quarterly Update - Business Wire 01.25.13 | 06:01 am
- ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2013 Financial Results - Business Wire 01.18.13 | 06:01 am
- ImmunoGen, Inc. Announces Webcast Of Presentation At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 01.02.13 | 06:01 am
- Amgen Takes Third License For Rights To Use ImmunoGen’s TAP Technology - Business Wire 12.19.12 | 06:12 am
- ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented At ASH - Business Wire 12.10.12 | 04:12 pm
- ImmunoGen, Inc. Announces Webcast Of Presentation At The Oppenheimer 23rd Annual Healthcare Conference - Business Wire 12.06.12 | 06:12 am
Partner Headlines for IMGN
- Immunogen Earnings: Here’s Why Investors are Buying Shares Now - Wall St. Cheat Sheet 04.26.13 | 11:04 am
- Market Wrap for Friday, April 12: Stocks Record Modest Losses; Treasuries Surge and Precious Metals Plunge - Benzinga 04.12.13 | 04:04 pm
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Roche Breast Cancer Drug To Succeed Herceptin - Investor's Business Daily 02.22.13 | 04:02 pm
- Show Me The Money: ADC Revenue Payloads Miss The Mark - Seeking Alpha 11.26.12 | 09:11 am
- UPDATE: Credit Suisse Initiates Immunogen at Neutral on Valuation - Benzinga 11.13.12 | 01:11 pm
- It's All Bad News For ImmunoGen After 1Q13 Earnings Release - Benzinga 10.26.12 | 04:10 pm
- Positive Results on Roche Candidate - Analyst Blog - NASDAQ 08.27.12 | 08:08 pm
- What's Moving The Market Today - Seeking Alpha 08.03.12 | 09:08 am
- Armed Antibodies: The Latest Weapon In The War Against Cancer - Seeking Alpha 07.23.12 | 09:07 am
